- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods -- Project Slated for Completion Coincident with…
NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announces the closing…
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey…
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB)…
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…
SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing…
VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to…
TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or…
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis…
The certification has the potential to open access to Islamic markets globally, expanding potential markets for Scilex’s innovative FDA approved…